加载中
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
收盘时
US$3.11
−US$0.15 · -4.60%
盘后
US$3.1381
+US$0.0281 · +0.90%
10月12日 19:54 ET
盘中时间采用ET。市场数据可能有所延迟。
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
日内区间
当前US$3.11
52周区间
当前US$3.11
盘中时间采用ET。市场数据可能有所延迟。
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
日内区间
当前US$3.11
52周区间
当前US$3.11
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 542.3万 USD | 599.3万 USD | 569.6万 USD | 432.4万 USD | 283.9万 USD |
| 销售、一般及管理费用 | 598.1万 USD | 411.5万 USD | 423.4万 USD | 596.3万 USD | 460.2万 USD |
| 营业费用 | 1140.4万 USD | 1010.8万 USD | 993万 USD | 1028.7万 USD | 744.1万 USD |
| 利息收入 | — | — | — | 2000 USD | 2000 USD |
| 利息支出 | 19.4万 USD | — | — | 5000 USD | — |
| 折旧和摊销 | 14.6万 USD | — | — | — | — |
| 营业利润 | −1140.4万 USD | −1010.8万 USD | −993万 USD | −1028.7万 USD | −744.1万 USD |
| 净利润 | −1287.9万 USD | −982.6万 USD | −928.9万 USD | −1008.3万 USD | −743.7万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅4项
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年8月31日 | 1:9 | — | — |
股票拆分 | 2026年3月10日 | 1:3 | — | — |
股票拆分 | 2025年6月13日 | 1:6 | — | — |
股票拆分 | 2022年8月10日 | 1:15 | — | — |
股票拆分 | 2019年6月21日 | 1:8 | — | — |
已生效 2026年8月31日
1:9
已生效 2026年3月10日
1:3
已生效 2025年6月13日
1:6
已生效 2022年8月10日
1:15
已生效 2019年6月21日
1:8
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
